Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc.) on July 29, 2021. The filing addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Accountant Resignation: OUM & Co., LLP resigned as the Company's independent registered public accounting firm effective July 29, 2021.
- Reason for Change: The resignation resulted from OUM's business combination (Acquisition) with WithumSmith+Brown, PC.
- New Appointment: WithumSmith+Brown, PC ("Withum") assumed the engagement and became the new independent registered public accounting firm on July 29, 2021, with Audit Committee approval.
- Audit History: OUM's reports for the years ended December 31, 2020, and 2019 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements between the Company and OUM regarding accounting principles or audit scope.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary on business operations. It confirms that during the two most recent fiscal years and through the date of the report, the Company did not consult Withum on any matters involving accounting principles or disagreements that would have been reportable under Regulation S-K.
Investor Verification Checklist
- Verify the transition of audit responsibilities from OUM & Co., LLP to WithumSmith+Brown, PC.
- Confirm that the resignation was due to a firm merger and not due to any dispute or financial irregularity.
- Note that the filing explicitly states no disagreements existed with the former auditor regarding accounting practices.
- Review the attached Exhibit 16.1 (OUM's letter to the Commission) for any additional context not summarized in the main text.